CRISPR Therapeutics, Prime Medicine, and Caribou Biosciences Announce June 2026 Investor Conference Schedules; Pipeline Updates Highlight Maturing CRISPR Clinical Portfolio

Three leading CRISPR gene editing companies announced investor conference presentations on May 28, 2026, providing a window into the state of the field heading into summer 2026: (1) CRISPR Therapeutics announced that senior management will present at the Jefferies Global Healthcare Conference (June 3, 9:55 a.m. ET), William Blair's 46th Annual Growth Stock Conference (June 3, 4:40 p.m. CT), and Goldman Sachs 47th Annual Global Healthcare Conference (June 9, 2:40 p.m. ET). Key topics will include the Casgevy commercial ramp (500+ patients treated globally, $43M Q1 2026 net revenue, $2.44B cash on hand), CTX310 (ANGPTL3 CRISPR Phase 1b for cardiovascular disease), allogeneic CAR-T programs (CTX340, CTX460), and the pediatric sBLA for Casgevy in ages 5–11. (2) Prime Medicine announced CEO Allan Reine will present at the Jefferies Global Healthcare Conference (June 4, 2026), providing updates on PM577 (Wilson disease prime editing, regulatory applications targeted H1 2026), PM647 (alpha-1 antitrypsin deficiency prime editing, IND mid-2026), and the company's broader prime editing pipeline. Prime also presented Wilson disease prime editing data at the ASGCT Annual Meeting (May 11–15, Boston). (3) Caribou Biosciences announced CEO Rachel Haurwitz will present at the Jefferies Global Healthcare Conference (June 4), discussing vispa-cel (CB-011, allogeneic CRISPR-edited CAR-T for relapsed/refractory multiple myeloma), which has achieved pivotal trial alignment with the FDA under RMAT designation. Caribou's Phase 1 data for CB-011 showed a 67% overall response rate in heavily pre-treated myeloma patients. These conference announcements highlight the breadth of the CRISPR clinical pipeline in mid-2026: approved therapy (Casgevy), near-BLA-ready (risto-cel for SCD), Phase 3-validated in vivo (lonvo-z for HAE, rolling BLA ongoing), multiple Phase 1 programs advancing, and next-generation prime editing entering first regulatory filings.